Trump DOJ Challenges Colorado’s Large-Capacity Magazine Ban in Second Amendment Lawsuit 
Coles “Down Down” Ruling Sparks Fresh Scrutiny of Australian Supermarket Pricing 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Cisco Restructures for AI Growth After Record Q3 Revenue 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
DOJ Ends Probe Into Fed Chair Jerome Powell, Boosting Kevin Warsh Confirmation Prospects 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Judge Rules DOGE Humanities Grant Cuts Unconstitutional 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
Aung San Suu Kyi Moved to House Arrest Amid Myanmar Political Crisis 
SK Hynix Nears $1 Trillion Market Value Amid South Korea’s AI-Driven Stock Market Surge 
Trump and IRS in Settlement Talks Over $10 Billion Tax Return Leak Lawsuit 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Dulles Airport Rebuild Plan Could Transform Washington’s Main International Gateway 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
